Sigrid’s CarbFence™ Delivers Appetite Control, Muscle-Preserving Weight Loss, and Exceptional Safety - Positioned for Global Roll-Out

Written By Brien L

Stockholm, Sweden – 18th August – Sigrid Therapeutics (Sigrid), the innoative Swedish consumer care company behind the patented SiPore® technology, today announced strong interim results from its U.S. real-world study of CarbFence™, a first-in-class, non-systemic medical food targeting appetite control, weight management, and metabolic health.

 

The 4-month, IRB-approved study was conducted by OvationLab, led by faculty from the University of Maryland School of Medicine, and enrolled 80 overweight or obese adults using CarbFence™ three times daily. Results at the one-month mark show a compelling mix of efficacy, safety, and consumer acceptability rarely seen in weight management products.

Key 1-Month Outcomes:

  • Exceptional Compliance – 95% of participants took CarbFence™ daily or missed only a few days

  • Powerful Appetite & Craving Control – Statistically significant improvements in:

      • Hunger ↓ 30%

      • Snacking ↓ 44%

      • Sugar cravings ↓ 40%

      • “Food coma” fatigue ↓ 47%

  • Clinically Meaningful Weight Loss with Muscle Preservation – 62% lost weight; responders averaged 6.7 lbs lost in the first month, with no loss of lean muscle mass

  • Visible Impact – Nearly half of participants reported improved clothing fit

  • Outstanding Safety – No serious adverse events; mild GI discomfort was rare and transient.

As part of the protocol, 21 participants are continuing for an additional 3 months to evaluate the durability of these benefits.

“U.S. real-world study shows CarbFence™ reduces appetite, drives weight loss, and preserves muscle – all while working locally in the gut.” - Prof. Tore Bengtsson, Co-founder & CSO, Sigrid.

 

“This study was designed to capture real-world use, giving us a clear picture of how people integrate CarbFence™ into daily life,” said Chris D’Adamo, Ph.D., University of Maryland School of Medicine and Principal Investigator. “The high compliance rates and consistent early outcomes strengthen the validity of the findings and set the stage for understanding longer-term benefits.”

Market Readiness
“With our science validated, manufacturing secured, and regulatory pathways cleared, we’re ready to scale CarbFence™ globally with a partner - bringing affordable, safe, and sustainable weight management to a market desperate for long-term solutions.” – Sana Alajmovic, Co-founder & CEO, Sigrid. 


About Sigrid Therapeutics
Sigrid Therapeutics is a Swedish innovative consumer care company redefining metabolic health with its patented SiPore® technology. Backed by over 15 years of research, SiPore® is a 100% natural mineral that works locally in the gut - mechanically capturing digestive enzymes to slow carbohydrate and fat breakdown, reducing calorie absorption without affecting essential micronutrients. This purely local, non-systemic mode of action regulates blood sugar, supports sustainable weight loss, and improves long-term health — all without entering the bloodstream or causing systemic side effects. The SiPore® portfolio includes:

  • CarbFence™ – a fast-acting, medical-grade liquid formula for rapid weight and blood sugar reduction in diabetics, prediabetics, and individuals living with overweight or obesity

  • Glucose Stabiliser – a daily dietary supplement for health-conscious consumers seeking long-term metabolic balance

 

Media contact

Sana Alajmovic
Co-founder & CEO
Sigrid Therapeutics
sana@sigridthx.com
+46 723 893 396

Brien L
Next

SIGRID’s Glucose Stabiliser Demonstrates Clinical Efficacy and U.S. Commercial Momentum Amid Growing Demand for Metabolic Health Solutions